Radiation recall dermatitis following ibrutinib therapy in a patient with breast cancer and non-Hodgkin lymphoma

We present the case of radiation recall dermatitis (RRD) induced by ibrutinib therapy in a patient with a history of breast cancer and non-Hodgkin lymphoma. There is currently only one other reported case of Bruton’s tyrosine kinase (BTK) inhibitor therapy-induced RRD in a patient with breast cancer and chronic lymphocytic leukaemia. This case highlights a potentially under-recognised risk of RRD associated with BTK inhibitors, emphasising the need for further research to clarify its pathophysiology and incidence in this treatment context. A deeper understanding of the dermatological side effects of BTK inhibitors can help providers better anticipate, recognise and manage patient symptoms.